-Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia- CAMPBELL, Calif. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc.

CAMPBELL, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos , Chief Executive Officer, will present at the Biotech Showcase™ 2020 on Monday, January 13, 2020 at 3:30 pm PT / 6:30pm ET .

CAMPBELL, Calif. , Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted a new stockholder rights plan to replace the Company’s stockholder rights plan that expired in

-Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56 week phase 4 study in obese adolescents- CAMPBELL, Calif. , Dec.

CAMPBELL, Calif. , Nov. 25, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos , Chief Executive Officer at VIVUS , will present at the Piper Jaffray 31st Annual Healthcare Conference at 1:10 P.M.

-Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo- CAMPBELL, Calif. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today

Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with

CAMPBELL, Calif. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resigned from its Board of Directors and all of its committees in order to increase their focus on other personal

CAMPBELL, Calif. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2019 after the market close on Tuesday, November 5, 2019 . The company will host a conference call beginning

CAMPBELL, Calif. , Oct. 21, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that John Amos , Chief Executive Officer, will participate in a panel discussion at the Cleveland Clinic 2019 Medical Innovation Summit, which is taking